Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Pediatric Nephrology
Erschienen in:

10.01.2022 | Original Article

Low dose rabbit antithymocyte globulin is non-inferior to higher dose in low-risk pediatric kidney transplant recipients

verfasst von: Vaka K. Sigurjonsdottir, Lynn Maestretti, Anne McGrath, Waldo Concepcion, Amy Gallo, Urdur Jonsdottir, Paul C. Grimm, Abanti Chaudhuri

Erschienen in: Pediatric Nephrology | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Currently, there is no consensus among pediatric kidney transplant centers regarding the use and regimen for immunosuppressive induction therapy.

Methods

In this single center, retrospective cohort study, pediatric kidney transplant recipients transplanted between 1 May 2013 and 1 May 2018 with rabbit antithymocyte globulin (rATG) induction were included. We stratified patients based on immunological risk, with high risk defined as those with repeat transplant, preformed donor specific antibody, current panel-reactive antibodies > 20%, 0 antigen match and/or African-American heritage. Outcome of interest was the incidence of biopsy proven acute rejection by 1 year.

Results

A total of 166 patients met inclusion criteria. Age of patients was 12 years (11 mo-21 y), (median, range), 21.5% received a living donor transplant and 50.6% were female. Low-immunologic-risk patients were divided into 2 groups, those who received the lower cumulative rATG dose of ≤ 3.5 mg/kg (n = 52) versus the higher cumulative dose of > 3.5 mg/kg (n = 47). The median total dose in the lower dose group was 3.1 (IQR 0.3) and 4.4 (IQR 0.8) in the higher dose group, P < 0.001. Rejection rate did not differ significantly between the 2 treatment groups (7/52 vs. 6/47). None in the lower dose group developed BK nephropathy versus 3 in the higher dose group. Graft loss due to BK nephropathy occurred in 1 patient in the higher dose group. Graft loss in the whole cohort at 12 months was a rare event (n = 1) with 99.5% graft survival and 100% patient survival.

Conclusions

Reduced rATG dosing (≤ 3.5 mg/kg) when compared to higher dosing (> 3.5 mg/kg) is safe and effective in low-risk pediatric kidney transplant recipients without increasing risk of rejection.

Graphical abstract

A higher resolution version of the Graphical abstract is available as Supplementary information
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Pascual J, Quereda C, Zamora J, Hernández D, Spanish Group for Evidence-Based Medicine in Renal Transplantation (2004) Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 78:1548–1556CrossRef
2.
Thomusch O, Wiesener M, Opgenoorth M, Pascher A et al (2016) Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Lancet 388:3006–3016CrossRef
3.
Tsampalieros A, Knoll GA, Molnar AO, Fergusson N et al (2017) Corticosteroid use and growth after pediatric solid organ transplantation: a systematic review and meta-analysis. Transplantation 101:694–703CrossRef
4.
Sarwal MM, Ettenger RB, Dharnidharka V, Benfield M et al (2012) Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up. Am J Transplant 12:2719–2729CrossRef
5.
Brennan DC, Daller JA, Lake KD, Cibrik D et al (2006) Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355:1967–1977CrossRef
6.
Koyawala N, Silber JH, Rosenbaum PR, Wang W et al (2017) Comparing outcomes between antibody induction therapies in kidney transplantation. J Am Soc Nephrol 28:2188–2200CrossRef
7.
Ashoor IF, Martz K, Galbiati S, Beyl RA et al (2020) Reassessing rabbit antithymocyte globulin induction in kidney transplantation (RETHINK): an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry. Transplant Direct 6:e598CrossRef
8.
Ault BH, Honaker MR, Osama Gaber A, Jones DP et al (2002) Short-term outcomes of thymoglobulin induction in pediatric renal transplant recipients. Pediatr Nephrol 17:815–818CrossRef
9.
Noël C, Abramowicz D, Durand D, Mourad G et al (2009) Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 20:1385–1392CrossRef
10.
Li L, Chaudhuri A, Chen A, Zhao X et al (2010) Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation. Transplantation 90:1516–1520CrossRef
11.
Ashoor IF, Beyl RA, Gupta C, Jain A et al (2021) Low dose anti-thymocyte globulin has no disadvantages to standard higher dose in pediatric kidney transplant recipients. Kidney Int Rep 6:995–1002CrossRef
12.
Roufosse C, Simmonds N, Clahsen-van Groningen M, Haas M et al (2018) A 2018 reference guide to the Banff classification of renal allograft pathology. Transplantation 102:1795–1814CrossRef
13.
Schwartz GJ, Work DF (2009) Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4:1832–1843CrossRef
14.
Chavers BM, Chang YC, Gillingham KJ, Matas A (2009) Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results. Transplantation 88:237–241CrossRef
15.
Hill P, Cross NB, Barnett ANR, Palmer SC et al (2017) Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cochrane Database Syst Rev 1:CD004759PubMed
16.
Brennan DC, Schnitzler MA (2008) Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 359:1736–1738CrossRef
17.
Dharnidharka VR, Stablein DM, Harmon WE (2004) Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 4:384–389CrossRef
18.
Jordan CL, Taber DJ, Kyle MO, Connelly J et al (2016) Incidence, risk factors, and outcomes of opportunistic infections in pediatric renal transplant recipients. Pediatr Transplant 20:44–48CrossRef
19.
Hertig A, Zuckermann A (2015) Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update. Transpl Immunol 32:179–187CrossRef
20.
Hall EC, Engels EA, Pfeiffer RM, Segev DL (2015) Association of antibody induction immunosuppression with cancer after kidney transplantation. Transplantation 99:1051–1057CrossRef
21.
de Paula MI, Bae S, Shaffer AA, Garonzik-Wang J et al (2020) The Influence of antithymocyte globulin dose on the incidence of CMV infection in high-risk kidney transplant recipients without pharmacological prophylaxis. Transplantation 104:2139–2147CrossRef
22.
Singh N, Rossi AP, Savic M, Rubocki RJ et al (2018) Tailored rabbit antithymocyte globulin induction dosing for kidney transplantation. Transplant Direct 4:e343CrossRef
23.
Grafals M, Smith B, Murakami N, Trabucco A et al (2014) Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study. PLoS One 9:e104408CrossRef
24.
Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES et al (2002) Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 73:1514–1518CrossRef
25.
Jin SE, Jeon S, Byon HJ, Hwang SJ (2017) Evaluation of tacrolimus sorption to PVC- and non-PVC-based tubes in administration sets: pump method vs. drip method. Int J Pharm 528:172–179CrossRef
26.
Jeong H, Kaplan B (2007) Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol 2:184–191CrossRef
27.
Kuypers DR, Claes K, Evenepoel P, Maes B et al (2004) Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 43:741–762CrossRef
28.
Min S, Papaz T, Lafreniere-Roula M, Nalli N et al (2018) A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation. Pediatr Transplant 22:e13285CrossRef
29.
van Delden C, Stampf S, Hirsch HH, Manuel O et al (2020) Burden and timeline of infectious diseases in the first year after solid organ transplantation in the Swiss transplant cohort study. Clin Infect Dis 71:e159–e169CrossRef
30.
Issa NC, Fishman JA (2009) Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 48:772–786CrossRef
31.
Dadhania D, Snopkowski C, Ding R, Muthukumar T et al (2008) Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication. Transplantation 86:521–528CrossRef
Metadaten
Titel
Low dose rabbit antithymocyte globulin is non-inferior to higher dose in low-risk pediatric kidney transplant recipients
verfasst von
Vaka K. Sigurjonsdottir
Lynn Maestretti
Anne McGrath
Waldo Concepcion
Amy Gallo
Urdur Jonsdottir
Paul C. Grimm
Abanti Chaudhuri
Publikationsdatum
10.01.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 9/2022
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-021-05407-y

Weitere Artikel der Ausgabe 9/2022

Female adolescent with recurrent anemia and thrombocytopenia: Answers

  • Clinical Quiz

Focal segmental glomerulosclerosis recurrence in a young adult with kidney transplant after mRNA COVID-19 vaccination

Acute kidney injury in pediatrics: an overview focusing on pathophysiology

  • Educational Review

Hemodynamic instability during connection to continuous kidney replacement therapy in critically ill pediatric patients

  • Original Article

Urinary metabolomics to develop predictors for pediatric acute kidney injury

  • Original Article

Is autosomal dominant polycystic kidney disease an early sweet disease?

  • Review

Neu im Fachgebiet Pädiatrie

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

Kann man Gestationsdiabetes mit oralen Antidiabetika behandeln?

Der Wunsch, Frauen mit Gestationsdiabetes eine orale Erstlinientherapie anbieten zu können, bleibt auch vorläufig ein Wunsch: Eine orale Stufentherapie hat sich in einer randomisierten Studie nicht als gleichwertig zu einer Insulintherapie erwiesen. 

Frühwarnzeichen für multiple Sklerose bei Kindern und Jugendlichen

Ein Forschungsteam aus Deutschland und Kanada hat eine Reihe metabolischer, okulärer, muskuloskelettaler, gastrointestinaler und kardiovaskulärer Symptome identifiziert, die bei Kindern und Jugendlichen der Diagnose einer multiplen Sklerose (MS) vorausgehen können.

Harnwegsinfekte: Was taugt die antibiotische Kurzzeittherapie bei Kindern?

In einer aktuellen Metaanalyse wurde untersucht, wie erfolgsversprechend eine verkürzte Antibiotikatherapie bei afebrilen Kindern mit Harnwegsinfekten im Vergleich zur Standardtherapie ist. In gewissen Fällen könnte die Kurzzeittherapie ausreichen. 

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise